Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by S. Dutta
Total Records ( 2 ) for S. Dutta
  S. Dutta , P.K. Mishra , G.M. Prasad , S. Shukla and S.K. Chaulya
  Next generation internet protocol IPv6 provides great solution to the problems associated with IPv4. Large address space of IPv6 solves the problem of lack of IP addresses which was a major concern with the enormous growth of the internet. The new version of protocol provides innumerable benefits like auto-configuration, simple header, multicasting, quality of service, etc. which improve the overall functionality of IPv6. In the present study, the benefits of IPv6 on IPv4 have been discussed in detail including the lacuna of IPv6 in present day scenario. The future challenges have also been identified during the implementation of IPv6.
  R. R Das , J. L Mathew , R. K Ratho and S. Dutta

Objective: This randomized, single-blinded trial was carried out to compare the sero-efficacy of hepatitis B vaccine administered to healthy infants by either of two schedules–birth, 6, 14 weeks or 6, 10 and 14 weeks.

Methods: The 74 infants born to HbsAg-negative mothers were randomized to receive recombinant hepatitis B vaccine at 0, 6 and 14 weeks (Group A) or 6, 10 and 14 weeks (Group B). Serum anti-HBs antibody titer was measured before the first dose and 6 months after the third dose by laboratory personnel blinded to the intervention. All participants received other vaccines as per the national immunization schedule.

Results: At 6 months after the third dose sero-conversion was 100% in both groups. A total of 97.3% of subjects in Group A were sero protected (>10 mIUml–1) with geometric mean titer (GMT) of 113.78 mIUml–1 and 94.6% in Group B (GMT 107.04 mIUml–1) [p = 0.8].

Conclusion: Hepatitis B vaccination by 0, 6 and 14 weeks and 6, 10 and 14 weeks schedules are comparable in terms of sero-efficacy.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility